Angel Lazo, MD
Internal Medicine · Secaucus, NJNPI 1932168523
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $166,990 of the $195,124 with a category attached, or 85.6%. 48 manufacturers reported payments, led by Novo Nordisk at 48.4% of the total. Reporting peaked in 2022 at $81,675 and has fallen 51.9% since, to $39,248 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,016 payments — averaging $192.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$94K
- Johnson & Johnson$50K
- Intuity Medical Inc$17K
- AstraZeneca$14K
- Intra-sana Laboratories$6K
- Amgen$5K
- plus $8K from 42 others
What the payments were for
- Speaking & faculty fees$166,99086%
- Travel & lodging$4,7992%
- Food & beverage$23,08712%
- Education$1300%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$49,107
- XARELTO$48,544
- RYBELSUS$31,997
- Pogo Automatic Blood Glucose Monitoring System$16,428
- AIRSUPRA$12,372
- Repatha$3,690
- AIMOVIG$492
- BREZTRI$357
- SAPIEN 3 Ultra RESILIA$357
- NURTEC ODT$245
- JARDIANCE$245
- Saxenda$233
- ENDURANT IIS$170
- FFRct$150
- Reltone 200 Mg$139
- GLYCATE$139
- Reltone 400 Mg$139
- Prolia$125
- FARXIGA$125
- EVENITY$122
How this compares
$195,124 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 489 | $516,198 |
| FarxigaDapagliflozin Propanediol | 466 | $501,109 |
| OzempicSemaglutide | 356 | $473,642 |
| JardianceEmpagliflozin | 296 | $325,492 |
| RybelsusSemaglutide | 134 | $242,040 |
| Diclofenac Sodium | 223 | $141,043 |
| TrulicityDulaglutide | 52 | $63,285 |
| ProliaDenosumab | 36 | $60,699 |
| DapagliflozinDapagliflozin Propanediol | 72 | $60,614 |
| VascepaIcosapent Ethyl | 62 | $50,829 |
| JanuviaSitagliptin Phosphate | 46 | $39,667 |
| TrintellixVortioxetine Hydrobromide | 63 | $37,293 |
| LinzessLinaclotide | 38 | $36,341 |
| EliquisApixaban | 40 | $35,145 |
| Metformin Er GastricMetformin Hcl | 47 | $33,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $94,390 | $715,682490 claims |
| Johnson & JohnsonXarelto | $50,312 | $516,198489 claims |
| AstraZenecaFarxiga | $14,463 | $501,109466 claims |
| Boehringer IngelheimJardiance, Jentadueto | $646 | $332,891310 claims |
| AbbVieLinzess, Creon | $518 | $68,13951 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $908 | $66,45666 claims |
| AmgenProlia | $5,263 | $60,69936 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $30 | $45,47782 claims |
| MerckJanuvia | $151 | $39,66746 claims |
| PfizerEliquis | $235 | $35,14540 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,049 | $35,05561 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $21,22723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Secaucus
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Linda WaseSkillman$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.